SCHEDULE: Sphera Funds Discloses 4.69% Stake in Outlook Therapeutics

Sphera Funds Management Ltd. and its affiliates reported a 4.69% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through exercisable warrants.

Summary

• Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP collectively reported beneficial ownership of 3,153,856 shares of Outlook Therapeutics, Inc. Common Stock.
• This ownership represents 4.69% of the total Common Stock outstanding.
• The percentage is calculated based on 64,114,399 shares of Common Stock outstanding as of December 16, 2025, as reported by Outlook Therapeutics in its Form 10-K filed on December 19, 2025, plus the 3,153,856 warrants beneficially owned by the reporting persons.
• The beneficial ownership primarily consists of warrants, with each warrant currently exercisable into one share of Common Stock.
• Specifically, 257,142 warrants (0.38%) are held by Sphera Global Healthcare Master Fund, and 2,896,714 warrants (4.31%) are held by Sphera Biotech Master Fund, L.P.
• Sphera Global Healthcare Management LP acts as the investment manager for both funds, and its general partner is Sphera Global Healthcare GP Ltd., which is 90% owned by Sphera Funds Management Ltd.
• The reporting persons disclaim beneficial ownership of the securities and disclaim the existence of a 'group' for purposes of Section 13(d) of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal. The disclosure of a significant institutional stake by a specialized healthcare fund suggests a degree of confidence in Outlook Therapeutics, Inc., although it does not provide new information on the issuer's operational or financial performance.

Positives

• The disclosure of a significant institutional stake (4.69%) by Sphera Funds Management Ltd. and its affiliates could be interpreted as a signal of confidence in Outlook Therapeutics, Inc. by a specialized healthcare investor.

Negatives

• The filing does not contain information regarding negative operational or financial aspects of Outlook Therapeutics, Inc.

Risks

• The reporting persons explicitly disclaim the existence of a 'group' for purposes of Section 13(d) of the Securities Exchange Act of 1934, despite potentially being deemed one, which could carry regulatory or legal implications for the reporting entities.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Outlook Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures, such as this Schedule 13G, provide transparency into significant investor positions. The accumulation of a nearly 5% stake by a specialized healthcare fund like Sphera Funds Management Ltd. in Outlook Therapeutics, Inc. suggests a strategic interest in the company's prospects within the biotechnology or pharmaceutical sector, particularly given Outlook Therapeutics' focus on ophthalmic therapeutics.

Comparison to Industry Standards

• StockSavvy.ai observes that a 4.69% stake is a notable position for an institutional investor, falling just below the 5% threshold that typically triggers more extensive reporting requirements (e.g., Schedule 13D, which implies intent to influence management).
• Compared to other institutional holdings in the biotech sector, a stake of this size is common for funds specializing in early to mid-stage companies, indicating a belief in the long-term potential of the underlying assets or pipeline.

Legal Proceedings

• The reporting persons explicitly disclaim the existence of a 'group' for purposes of Section 13(d) of the Securities Exchange Act of 1934, which is a legal nuance related to beneficial ownership reporting.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a substantial stake may instill confidence among existing shareholders and attract new investors, potentially influencing trading activity.
• Management: The presence of a large institutional holder could lead to increased scrutiny or engagement from the investor regarding corporate strategy and performance, although the filing states no intent to influence control.

Key Dates

Keywords

Outlook Therapeutics, Sphera Funds Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Healthcare Sector